3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
104
Neoplasms
13
Neoplasm Metastasis
8
Sarcoma
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Melanoma
5
Leukemia, Myeloid, Acute
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Liposarcoma
4
Multiple Myeloma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Breast Diseases
3
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm, Residual
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Inflammation
2
Estrogen Receptor-positive Breast Cancer
2
Esophageal Squamous Cell Carcinoma
2
Interventions
Cyclophosphamide
8
fludarabine phosphate
6
fludarabine
5
Bendamustine Hydrochloride
4
Busulfan
3
AP 1903 reagent
3
pembrolizumab
2
Tacrolimus
2
Mycophenolic Acid
2
thymoglobulin
1
pimonidazole
1
palbociclib
1
ibritumomab tiuxetan
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Rivaroxaban
1
Rituximab
1
Radiotherapy
1
Plasmalyte A
1
Pharmacogenomic Testing
1
Melphalan
1
Hydroxychloroquine
1
Etoposide
1
Dimethyl Sulfoxide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immune System Diseases
×
palbociclib
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled